RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin.

Wendy Muñoz-MontañoSae Muñiz-HernándezAlejandro Avilés-SalasRodrigo CatalánLuis Lara-MejíaSuraj Samtani-BassarmalAndres F CardonaJorge Mendoza-DesiónDaniel Hernández-CuetoAltagracia MaldonadoGuillermina Baay-GuzmánSara Huerta-YepesArrieta Oscar

Published in: BMC cancer (2021)

ERCC1 and RRM1 are useful biomarkers that predict better survival outcomes in patients with advanced MPM treated with continuous infusion of gemcitabine plus cisplatin.

Keyphrases

locally advanced
low dose
squamous cell carcinoma
rectal cancer
neoadjuvant chemotherapy
dna repair
phase ii study
radiation therapy
high dose
small cell lung cancer
newly diagnosed
oxidative stress
open label
clinical trial